Key result
Following reports of increased stent thrombosis risk at ESC 2006, overall deployment of drug-eluting stents fell sharply from 83% to 58%, with dramatic reductions in off-label indications.
Observational
Yes
Following reports of late stent thrombosis in 2006, real-world use of drug-eluting stents fell dramatically by 2008, especially for off-label indications such as STEMI.
Answers are grounded in this paper and cite their sources.
Safety signals can rapidly curb off-label DES use; leaves open whether this shift improved net outcomes.
BACKGROUND: We sought to examine the temporal variations in the rate of both bare-metal stent (BMS) and drug-eluting stent (DES) use for off-label indications after the reports of an increased risk of very late stent thrombosis in patients with DES at the 2006 meeting of the European Society of Cardiology (ESC). HYPOTHESIS: To determine whether the decrease in use of DES has affected both on and off-label indications. METHODS: The study cohort included patients undergoing coronary intervention in a large regional registry, the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Patient demographic and clinical characteristics for patients with DES in the third quarter of 2006 (pre-ESC) were compared to those from the fourth quarter of 2008 (post-guideline changes). Use of DES for off-label indications, such as ST-segment elevation myocardial infarction (STEMI), in-stent restenosis (ISR), and saphenous vein graft (SVG) interventions, were evaluated. RESULTS: The overall deployment of DES fell sharply from 83% pre-ESC to a plateau of 58% in the first quarter of 2008. This corresponded to a rise in BMS use, while angioplasty procedures stayed the same. The STEMI subgroup showed the most dramatic change, from 78% to only 36%. Off-label use in SVGs showed a similar trend, from 74% to 43%. Drug-eluting stent deployment for ISR was less affected, though it also fell 25% (from 79%-56%). CONCLUSIONS: The use of DES has fallen dramatically from June 2006 to December 2008, particularly for nonapproved indications. Our study provides a real-world assessment of contemporary change in DES use in response to the presentation of negative observational studies.
No takes yet. Share an insight, caveat, or question.
Gualano et al. (2010) conducted an observational in Coronary intervention. Reports of increased risk of very late stent thrombosis at ESC 2006 vs. Pre-ESC 2006 period was evaluated on Overall deployment of drug-eluting stents (DES). Following reports of increased stent thrombosis risk at ESC 2006, overall deployment of drug-eluting stents fell sharply from 83% to 58%, with dramatic reductions in off-label indications.
Synapse has enriched 10 related papers. Consider them for comparative context: